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A B S T R A C T
In the recent years, much attention has been focused on identifying bioactive compounds from medicinal plants
that could be employed in therapeutics, which is attributed to their potent pharmacological actions and better
toxicological profile. One such example that has come into the light with considerable interest is the pentacyclic
triterpenoid, celastrol, which has been found to provide substantial therapeutic properties in a variety of dis-
eases. In an effort to further accelerate its potential to be utilized in clinical practice in the future; along with
advancing technologies in the field of drug discovery and development, different researchers have been in-
vestigating on the various mechanisms and immunological targets of celastrol that underlie its broad spectrum of
pharmacological properties. In this review, we have collated the various research findings related to the mo-
lecular modulators responsible for different pharmacological activities shown by celastrol. Our review will be of
interest to the herbal, biological, molecular scientist and by providing a quick snapshot about celastrol giving a
new direction in the area of herbal drug discovery and development.
1. Introduction
Plant derived remedies have become novel candidates in the para-
digm of drug discovery and development due to potent pharmacolo-
gical effects and better toxicology profiles [1–15]. Celastrol is a
bioactive constituent extracted from Tripterygium wilfordii (TW), a tra-
ditional Chinese medicinal herb commonly referred to as ‘Thunder of
God Vine’ [16,17]. Also called tripterine, it belongs to a class of natural
compounds known as triterpene quinine methides and is made up of
five cyclic rings, further classifying it as a pentacyclic triterpenoid
[17,18] (Fig. 1). Extensive experimentation throughout the years have
shown that celastrol exhibits curative properties in the treatment of
cancer, obesity, inflammatory, auto-immune and neurodegenerative
diseases through the modulation of a variety of molecular targets.
Primarily, it affects protein function through the formation of covalent
Michael adducts (Fig. 2).
1.1. Anti-cancer properties
Recent studies have shown celastrol to be a promising anti-cancer
drug, and this property has been regarded as the most widely experi-
mented property of the compound. Carcinogenesis, a complex process
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involved in cancer causes genetic alteration at a cellular and molecular
level, which can be further divided into three phrases; initiation, pro-
motion, and progression. Studies on the effect of celastrol have been
carried out on various cancer cell lines such as prostate, breast, lung,
skin and gastric cancers. Celastrol has been shown to carry out its anti-
cancer properties through the modulation of different molecular targets
that aims to; (i) promote apoptosis/inhibit proliferation, (ii) inhibit
angiogenesis and (iii) suppress cell invasion and metastasis [16,18,19].
Out of the many molecular targets involved in regulating cancer, the
nuclear factor- κB (NF-κB) remains to be one of the most significant in
the treatment of cancer. The activation of NF-κB inhibits apoptosis and
induces pro-inflammatory cytokines, further promoting tumour growth.
Therefore, inhibiting NF-κB may increase the sensitivity of tumour cells
towards the apoptotic activity of TNF- α [16,19–21]. In agreement, a
recent study in 2018 by Sethi et al., demonstrated that the activity of
NF-κB was suppressed due to an inhibitory effect on transforming
growth factor-activated kinase 1 (TAK1) and the activation of IκBα
kinase [22]. Besides that, celastrol also inhibited the phosphorylation
and degradation of IκBα, the nuclear translocation and phosphorylation
of the p65 protein, and NF-κB-mediated reporter gene expression, all
which seems to be induced by TNF-α. This promotes apoptosis and
prevents proliferation, further enhancing tumour cell death in a variety
of cancer cell lines [22,23]. This effect can be seen in a study by Zhao
et al. on human myeloma cells, where upon celastrol administration, a
cell proliferation inhibitory rate of over 80% was observed. Further-
more, increased apoptotic cell percentage could be observed [24].
Another anticancer property of celastrol can be ascribed to the in-
hibition of tumour angiogenesis [25]. Pang et al., showed that celastrol
successfully inhibited tumour growth and angiogenesis in a human
prostate tumour xenograft mouse model. Upon administration of ce-
lastrol at 2 mg/kg/day, the tumour weight was reduced by approxi-
mately 73% after 16 days, compared to the control, where an increase
in tumour weight was observed [26]. Another study conducted on
human glioma xenograft mice model showed that the density of micro
vessel in the xenografts was reduced upon administration of 2mg/kg of
celastrol (24.5 ± 2.66 vessel/mm2) compared to the control
(37 ± 6.04 vessel/mm2) [27]. The major mechanism attributed to
these observations is the inhibition of the AKT/mTOR/P70S6K signal-
ling pathway, and downregulation of vascular endothelial growth
factor receptors (VEGFR); VEGFR-1 and VEGFR-2. The downregulation
of both VEGFR-1 and VEGFR-2 seems to be a possible method to de-
crease cell sensitivity towards vascular endothelial growth factor
(VEGF), thereby resulting in decreased vascular permeability, de-
creased migration and proliferation of endothelial cells [28].
Celastrol has also been reported to inhibit tumour invasion and
cancer metastasis. A recent study by Yang et al., on mice implanted
Fig. 1. Chemical structure of celastrol (C29H38O4).
Fig. 2. Formation of Michael adducts through the binding of electrophilic sites on quinone methide rings of celastrol (blue) and nucleophilic thiol groups of cysteine
residues (pink) (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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with 4T1 (breast cancer) tumour cells showed that the number of me-
tastasis in the celastrol treated group was significantly lesser (less than
5) compared to the control group (up to 15). This can be ascribed to the
downregulation in the signal transducer and activator of transcription 6
(STAT6) signalling pathway through inhibited phosphorylation,
thereby inhibiting M2-like polarization of tumour-associated macro-
phages (TAMs) which leads to suppressed cancer metastasis [29,30].
Moreover, studies conducted on lung adenocarcinoma cells [22] and
breast cancer cells [31] demonstrated that celastrol inhibits the in-
vasive activity from TNF, and this is correlated with the inhibition of
matrix metalloproteinase-9 (MMP-9) and NF-κB pathway suppression
[32]. In 2017, Wu et al., proved that celastrol inhibited migration and
invasion of human chondrosarcoma cells with maximum inhibition at
5mg/L of celastrol. This is achieved through the suppression of the cell
proliferation regulating inhibitor of protein phosphatase 2 A/c-MYC
(CIP2 A/c-MYC) signalling pathway, downregulating the expression of
CIP2 A protein, which results not only in decreased tumour invasion,
but also decreased cell proliferation and induced apoptosis [33].
1.2. Anti-inflammatory properties
Various studies have provided evidence in favour of celastrol pos-
sessing anti-inflammatory properties that may be beneficial to a variety
of inflammatory diseases such as asthma, rheumatoid arthritis, in-
flammatory bowel disease and systemic lupus erythematosus (SLE).
Celastrol exerts its anti-inflammatory effects mainly through the mod-
ulation of a variety of inflammation mediators, particularly mediators
induced by lipopolysaccharides (LPS) [34]. Celastrol also suppresses
the production of pro-inflammatory cytokines; TNF-α, IL-2, IL-8, IFN-γ,
proinflammatory enzymes; nitric oxide synthase (NOS), cyclooxygenase
(COX-1, COX-2), transcription factors; nuclear factor kappa B (NFκB),
and adhesion molecules [35,36]. Besides that, celastrol has also been
shown to alleviate inflammation through the promotion of mitochon-
drial autophagy via the nuclear receptor Nur77 [37].
Rheumatoid arthritis (RA) is an inflammatory disorder
distinguished by joint inflammation, cartilage and bone damage leading
to loss of function and deformities. Treatment of RA has been accom-
panied with notable adverse effects, posing a huge challenge in the
clinical field [38,39]. This leads to an increasing interest in searching
for new remedies such as celastrol. Studies carried out on rat arthritis
models showed inhibition in swelling recurrence of up to an average of
55.25% when using 10mg/kg/day of celastrol and 81.60% when using
20mg/kg/day of celastrol. This is due to the suppressive effect of ce-
lastrol on the secretion of pro-inflammatory cytokines, IL-1β from the
inhibition of caspase-1 activation, and TNF- α. This leads to decreased
immune cell infiltration and proliferation into the synovial membrane,
decreasing swelling and bone destruction [40,41]. The Toll-like re-
ceptor 4 (TLR4)/NFκB pathway was also inhibited by the administra-
tion of celastrol, which leads to the suppression of metalloproteinase-9
(MMP-9) expression, thereby decreasing cell infiltration from fibro-
blast-like synoviocytes [34]. This shows that celastrol remains an in-
teresting candidate in treating rheumatoid arthritis.
In the case of inflammatory bowel diseases, Pinna et al., discovered
that celastrol successfully decreases the levels of pro-inflammatory cy-
tokines, namely TNF- α, IL-1β, IL-6 and IL-8 in biopsies of the inflamed
intestinal mucosa of patients with Crohn’s disease. This occurs through
the inhibition of the translocation of NFκB receptor induced by LPS into
the nucleus, thereby inhibiting cytokine transcription [42]. Further-
more, studies carried out on dextran sulphate sodium (DSS) induced
mice to determine the activity of celastrol on ulcerative colitis (UC)
have shown alleviation in colon injury, reduced severity and prevents
impairment of intestinal homeostasis. This is carried out through (i)
decreased production of TNF- α and IL-1β, (ii) increase in IL-10 levels,
(iii) countering oxidative stress in the colon and (iv) upregulation of e-
cadherin expression. Moreover, celastrol also inhibits the necroptosis
process in colonic epithelial cells through suppression of the RIP3/
MLKL pathway [43,44].
Besides that, asthma, which is a condition affecting the conducting
airways, is characterized by excessive bronchiole contraction, resulting
in reversible airflow obstruction. Currently, the cornerstone for the
Fig. 3. Summary of the pharmacological actions of celastrol through modulation of various molecular targets.
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treatment of asthma is inhaled corticosteroids (ICS). However, the in-
creasing incidence of steroid-resistant asthma limits the use of ICS,
warranting the discovery of new compounds as an alternative treatment
[45,46]. Many studies have reported the effect of celastrol on steroid
resistant asthma. In an experiment carried out on obese asthmatic mice,
Zheng et al., demonstrated that celastrol produces an effect on IL-17,
which inhibits the production and differentiation of CD4+T cells
(Th17). It is proposed that Th17 cells play a major role in mediating
SRA. It was shown that both the serum level and lung expression of IL-
17 A were significantly lower upon administration of celastrol. This
inhibition leads to an alleviation in airway hyper-responsiveness
(AHR), as the decreased amount in Th17 cells is correlated with a re-
duction in neutrophilic inflammatory response in the lungs. Generally,
this leads to a reduction in inflammation and the thickness of wall in
obese asthmatic mice [47,48]. Furthermore, celastrol has also been
shown to regulate the imbalance between matric metalloproteinases
(MMPs); MMP-2 and MMP-9, and tissue inhibitors of
metalloproteinases (TIMPs); TIMP-1 and TIMP-2. This results in re-
duced cellular infiltration and accumulation, reduced airway model-
ling, and alleviation in asthma symptoms [49,50]. The balance between
MMPs and TIMPs occur as celastrol inhibits the activity of the NK-ϰB
receptor, and the phosphorylation of mitogen-activated protein kinases
(MAPK) found in broncho-alveolar lavage cells and lung tissues. This
decreases the production of inflammatory cytokines responsible for
asthmatic symptoms such as TNF-α and IL-13 [49].
On the other hand, SLE is a complex autoimmune disorder char-
acterized by elevated levels of autoantibodies in the body, affecting
different organ systems [51]. In 2005, a study conducted out by Li et al.,
in BALB/c mice exhibited decreased levels of circulating im-
munoglobulin; anti-ss DNA, anti-ds DNA, and IgG antibodies upon ad-
ministration of celastrol at 12mg/kg/day. This result was better in
comparison to the standard treatment of prednisolone at 5mg/kg/day.
Furthermore, the production of IL-10 and NO were also decreased [52].
In the agreement, studies using NZBxW mice model also showed a
Table 1
Summary of studies and trials that report the various pharmacological properties of celastrol.
Property Findings Type of study Reference(s)
Anti-cancer Promotes apoptosis and prevents cell proliferation, thus enhancing tumour cell death. In-vitro on human cell lines [22]
Cell proliferation inhibitory rate of over 80% was observed. In addition, increased apoptotic
cell percentage was observed.
In-vitro on human myeloma cells [24]
Tumour weight reduced by approximately 73% after administration of celastrol at 2 mg/kg/day
for 16 days.
In-vitro on human prostate tumour
xenograft mouse model
[26]
The density of micro vessels in xenografts was reduced upon administration of 2 mg/kg
celastrol.
In-vitro on human glioma xenograft mice
model
[27]
The number of metastasis in celastrol treated group was significantly lesser as compared to the
control group.
In-vivo on mice implanted with 4T1 tumour
cells
[29]
Migration and invasion of human chondrosarcoma cells inhibited with a maximal inhibitory
concentration of 5 mg/L.
In-vitro on human chondrosarcoma cell lines
SW1353
[33]
Anti-inflammatory Average inhibition in swelling recurrence up to 55.25% using 10mg/kg/day celastrol, and up
to 81.60% using 20mg/kg/day celastrol.
In addition, decreased immune cell filtration and proliferation into the synovial membrane,
leading to decreased swelling and bone destruction.
In-vivo on adjuvant-induced arthritis rats [40]
Decreased levels of proinflammatory cytokines, such as TNF-alpha, IL-1β, IL-6 and IL-8 In-vitro on biopsies of inflamed intestinal
mucosa in Crohn’s disease
[42]
Alleviation in colon injury, as well as reduced severity and prevention of intestinal homeostasis
impairment.
In-vivo on dextran sulphate sodium-induced
mice
[43]
Both serum and lung expression of IL-17 A significantly decreased upon administration of
celastrol. In addition, alleviation of airway hyper-responsiveness was observed and there was
overall reduction in inflammation and thickness of airway walls.
In-vivo on obese asthmatic mice [47]
Decreased levels of circulating immunoglobulin, anti-ss DNA, anti-ds DNA and IgG antibodies
upon administration of celastrol at 12mg/kg/day. Moreover, decreased production of IL-10
and NO was observed.
In-vivo on BALB/c mice [52]
Decreased serum antibodies which alleviates clinical symptoms of systemic lupus
erythematosus, thus improving survival rate.
In-vivo on NZBxW mice models [53]
Anti-obesity Reduction in body weight of leptin-resistant mice up to 45% through a decrease in the
consumption of food.
In-vivo on leptin-resistant mice [59]
Celastrol prevented accumulation of lipid and decreases expression of adipocyte-specific
markers.
In-vitro signalling studies in 3T3-L1
adipocytes
[61]
Decrease in levels of low-density lipoprotein and triglyceride was observed in obese mice. In-vivo on Male Sprague-Dawley rats fed
with high fat emulsion
[62]
Neuroprotective Increased removal of cytotoxic haem and reduced formation of haem-amyloid beta complexes
were observed, that are responsible for symptoms of Alzheimer’s disease.
In-vitro on cerebral cortical cultures of 19
days embryonic rats
[65,66]
Prevention of Aβ molecule accumulation and increased clearance seen. In-vivo on APP/PS1 mice [67]
Increased Aβ clearance, decreased oligomerization of Aβ, restoration of tau homeostasis and
inhibition of neurons apoptosis observed.
In-vitro on Cos-1, Hela and 293 cells line [68]
Reduced aggregation and accumulation of α -synuclein protein that is responsible for the
pathogenesis of Parkinson’s disease. Moreover, decreased liberation of reactive oxygen species,
cytochrome C and apoptosis promotion factors observed, thus showing prevention of further
cell death.
In-vitro on human neuroblastoma SH-SY5Y
cells
[69]
Anti-diabetic • Lower mean fasting plasma glucose level in celastrol-treated mice after 8 weeks.• Approximate drop of 42% in HbA1C levels and drop of 30% in basal glucose at the time of
60minutes of celastrol treatment.
• Decrease in epididymal fat mass and saturated fatty acid levels, leading to decreased
inflammation and oxidative stress.
• Lower creatinine levels in celastrol-treated mice.
In-vivo on mice [75]
• Celastrol significantly improved uptake of glucose up to 86% upon insulin stimulation.• Rise in protein phosphorylation of insulin signalling cascades.• Elevation in levels of phosphorylated 5’ AMP-activated protein kinase and decreased
activity of protein kinase C theta.
In-vitro on human skeletal muscle cells [82]
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decrease in serum autoantibodies, in addition alleviating clinical
symptoms and improving survival rate [53]. The reduction in auto-
antibody production in SLE can be correlated to celastrol’s ability to
inhibit the formation of neutrophil extracellular traps (NETs) which
causes endothelial damage leading to inflammation. This inhibition is
mainly associated with the ability of celastrol to inhibit phosphoryla-
tion of spleen tyrosine kinase (SYK) and mitogen-activated protein ki-
nase-kinase (MAPKK/MEK), thereby preventing neutrophil oxidative
burst and subsequent formation of NETs [54,55].
Together, these findings have demonstrated that celastrol possesses
the capability to treat arthritis, inflammatory bowel diseases, asthma,
and SLE through the modulation of different molecular targets, and this
may pave a pathway for further exploration towards the treatment of
other inflammatory diseases.
1.3. Anti-obesity properties
Obesity is the world’s foremost cause of mortality, as it is accom-
panied by other health risks such as cardiovascular disease, cancer,
poor mental health, and diabetes mellitus. Obesity is defined as the
accumulation of excess fat, leading to a body mass index of more than
30 kg/m2. Obesity remains a huge disease burden as there are limited
remedies available, which encourages a search for new anti-obesity
drugs [56,57]. In regard to this, celastrol has been demonstrated to
show effects that control obesity in several mice models. Leptin, a
hormone produced by adipose tissue, is a hallmark of obesity as it is
responsible for suppressing food intake and regulating energy ex-
penditure [58]. However, the development of leptin resistance has
become a huge problem in the treatment of obesity, leading to a de-
crease in weight loss. Celastrol possesses the ability to reverse leptin
resistance in cells, thereby increasing leptin sensitivity [59].
A study by Liu et al., in 2015 showed that celastrol reduced the body
weight of leptin-resistant mice up to 45% through a decrease in the
consumption of food. However, it showed no change in the lean mass of
normal mice. Additionally, an increase in leptin levels in lean-mice has
shown an increase in the effect of celastrol on the reduction of food
consumption and body weight. This shows that the action of celastrol is
dependent on the concentration of leptin, further strengthening the
hypothesis of celastrol being a leptin sensitizer [54]. The increase in
leptin sensitivity is due to the alleviation in hypothalamic endoplasmic
reticulum stress through a decrease in PERK phosphorylation and
SERCA2B protein levels by celastrol [59,60].
Besides that, a team led by Choi et al., have managed to demon-
strate that celastrol prevents the accumulation of lipid and decreases
the expression adipocyte-specific markers via an inhibitory effect on the
differentiation of adipocytes. This decrease is associated with a reduc-
tion in GPDH activity and inhibition of PPARγ2- and C/EBPα-induced
transcriptional activity in 3T3-L1 adipocytes [61]. Another study
showed that celastrol exerts its anti-obesity actions through (i) in-
hibiting the generation of reactive oxygen species (ROS), (ii) increasing
the activity of antioxidant enzymes, and (iii) inhibiting the activity of
the enzyme NADPH oxidase. The combination of these actions is as-
sociated with a decrease in the levels of low-density lipoprotein (LDL)
and triglyceride in obese mice [62]. However, the exact mechanism of
celastrol on obesity has yet to be elucidated and further studies are
required to determine its potential for clinical application in the
treatment of obesity.
1.4. Neuroprotective properties
Studies have identified celastrol as a potential agent in slowing
down neurodegenerative diseases namely Alzheimer’s disease (AD) and
Parkinson’s disease (PD) in animal models. Neurodegenerative diseases
are characterized by misfolding and continuous polymerisation of
proteins leading to accumulation of protein aggregates. This process is
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heat shock proteins (HSP), with the class of HSP70 playing the most
significant role in influencing protein refolding, reactivation and pre-
venting the formation of aggregates [63,64]. Celastrol has been shown
to induce and modulate the activity of these HSPs in the cerebral cortex,
thereby exerting a neuroprotective effect [65,66].
Two studies conducted by Chow et al., during the years 2013-14
have demonstrated that celastrol induces the expression of a variety of
HSP classes, such as HSP27 and HSP32 in glial cells and HSP70 in
neurons in rat models. The increased expression of HSP32 results in the
increase in the removal of cytotoxic haem which is elevated in AD
through conversion into beneficial antioxidant by-products, reducing
the formation of haem-amyloid beta complexes responsible for AD
symptoms [66]. As for HSP27, its increased expression allows it to
normalize synaptic excitability in AD through preventing the accumu-
lation of Aβ molecules and increasing its clearance [67]. On the other
hand, the induction of HSP70 confers the greatest protective effects,
contributing not only to its neuroprotective properties but also towards
anti-inflammatory properties. The protein works by (i) promotion of
apoptosis through TNF, and (ii) suppressing inflammatory responses
through NFκB receptor. In the AD, the combination of these mechan-
isms results in increased Aβ clearance, decreased oligomerization of Aβ,
restoration of tau homeostasis, and inhibiting the apoptosis of neurons
[68].
Moreover, the neuroprotective properties of celastrol also stems
from its ability to induce autophagy, which plays a crucial role in both
AD and PD [69]. Autophagy, in short, refers to the degradation of
protein aggregates and is largely responsible for removing toxic or
damaged proteins. In PD, this mechanism is deregulated, causing the
toxic protein aggregates to accumulate and collect in the brain. More-
over, mitochondrial clearance is further impaired, leading to an accu-
mulation of damaged mitochondria [70]. Deng et.al conducted a study
to test the effects of celastrol using human neuroblastoma SH-SY5Y cells
to demonstrate autophagy induction. Through this, it is shown that
celastrol protected the cells from death through enhanced autophagy
activation. The activation of autophagy reduced the aggregation and
accumulation of the α-synuclein protein which is believed to be ac-
countable for the pathogenesis of PD. In addition, it also leads to “mi-
tophagy”, which is the elimination of damaged and dysfunctional mi-
tochondria. This decreases the liberation of reactive oxygen species
(ROS), cytochrome C and apoptosis promotion factors, preventing fur-
ther cell death [71,72].
1.5. Anti-diabetic properties
Lately, the prevalence of diabetes mellitus has substantially in-
creased, resulting in major health challenges and increasing disease
burden. Type 2 diabetes mellitus, where decreased utilization of insulin
by tissues due to desensitisation occurs is known as insulin resistance
which leads to a condition known as hyperglycaemia [73,74]. This has
shifted the focus of drug development and discovery to synthetic drugs
formulated from medicinal plants, such as celastrol. Studies of celastrol
on Type 2 diabetes models have been extensively studied throughout
the years, and the compound has demonstrated several anti-diabetic
properties, particularly on insulin-resistant models. Kim et al., treated
insulin resistant diabetic mice with celastrol for a duration of 2 months
and discovered that the compound significantly decreased fasting
plasma glucose and haemoglobin A1c levels (HbA1C). This was seen by
a lower mean fasting plasma glucose in celastrol treated diabetic mice
in comparison to non-treated diabetic mice, with values of 16.2 mmol
and 32.1 mmol respectively after 8 weeks of treatment. Moreover, an
approximate drop of 42% in HbA1C levels and a drop in basal glucose
by 30% at time of 60min could be observed [75]. This effect can be
attributed to the inhibition of NFκB activation, as insulin resistance has
been shown to be associated with this protein complex. This inhibition
is a direct result of celastrol’s ability to inhibit the degradation and
phosphorylation of the IκBα kinase through modification of a cysteine
residue of the kinase [76,77]. Concurrently, a decrease in epididymal
fat mass and saturated fatty acid levels were observed, and this led to an
overall decrease in inflammation and oxidative stress, causing a re-
duction in diabetic nephropathy. This was further shown by lower
creatinine levels in the celastrol treated diabetic mice (29 μmol) - in
contrast to both the non-treated diabetic mice (45 μmol) and non-
treated normal mice (35 μmol) [75]. Similarly, the effect was due to the
inhibition of NFκB by celastrol, leading to improved renal lipid meta-
bolism, hence exerting a reno-protective effect [78,79].
Type 2 diabetes has been implicated with mitochondrial dysfunc-
tion and inflammation, hence, celastrol has been shown to modulate
these processes [80]. Mitochondrial dysfunction leads to a decrease in
mitochondrial oxidation of substances such as lipid, which reduces the
occurrence of oxidative phosphorylation, hence affecting insulin sen-
sitivity [81]. In 2015, intensive studies have demonstrated the ability of
celastrol to modulate the signalling pathways of insulin in an in vitro
model of insulin resistant human skeletal muscle cells. Results of the
study have shown that celastrol significantly improved the uptake of
glucose by up to 86% upon insulin stimulation [82]. This enhancement
was related to the regulation of PI3K/Akt pathways, where its stimu-
lation affects mitochondrial functions through the promotion of GLUT4
translocation. This stimulation is achieved through the NFκB receptor,
where celastrol has been known to inhibit [83]. (1,2) A rise in the
protein phosphorylation of insulin signalling cascades such as NFκB
could also be observed, resulting in lower IκBα kinase activity. In ad-
dition, the ameliorative properties of celastrol caused an elevation in
the levels of phosphorylated 5′AMP-activated protein kinase (AMPK),
while concurrently, the activity of protein kinase C theta (PKC- θ) was
decreased [82]. AMPK is an enzyme that has been reported to be a key
regulator in lipid and glucose metabolism. Activation of this enzyme
causes an antagonistic effect on pro-inflammatory cytokines, which
modulates the process of mitochondrial dysfunction [81,84]. As for
PKC- θ, downregulation of this protein results in a decrease in total and
cytosolic diacylglycerol (DAG), which has a positive effect on insulin
sensitivity due to the ability of DAG to regulate insulin signalling
[85,86]. These findings have shown the ability of celastrol as a potent
anti-diabetic agent primarily in the cases of insulin resistance (Fig. 3
and Table 1).
2. Prospects for clinical use
In paving the way for celastrol to be utilised therapeutically, several
clinical trials had been conducted for a variety of diseases using TW
plant extract. A randomised clinical trial involving 35 rheumatoid ar-
thritis patients was conducted in 2002, whereby 80% of the patients
who were given high-dose TW extract (360mg/day) and 40% of pa-
tients who were given low-dose TW extract (180mg/day) had shown
American College of Rheumatology 20% (ACR20) response criteria,
signifying improvement in both inflammation and physical function, in
contrast to those taking placebo. Nevertheless, diarrhoea and nausea
were identified as the most common adverse effects following TW
therapy [20,87]. Another randomised trial on RA conducted by Gold-
bach-Mansky in 2009 had also demonstrated that 68% of patients
treated using TW extract (60mg three times daily) achieved ACR20
response after six months, as compared to 36% in patients treated using
sulfasalazine. However, several adverse effects were reported in pa-
tients on TW, such as diarrhoea, nausea, abdominal pain, dyspepsia, as
well as upper respiratory tract infection [20,88].
On the other hand, TW had also been employed in the clinical trials
for cancer. A Phase I trial for the treatment of solid tumour was per-
formed by Kitzen et al. in 2009, using water-soluble derivative of
triptolide (F60008), which is a TW diterpernoid. F60008 was given
intravenously in 35 cycles to patients with advanced solid tumours. The
most common adverse effects observed in the study include mild
anaemia, diarrhea, nausea and vomiting, constipation, and fatigue
[20,89].
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Besides, TW extract was also studied in diabetic nephropathy. In a
randomized clinical trial performed in 2013 by Yongchun et al., 65
patients were randomized into 2 treatment groups; (i) 120mg per day
of TW extract for 3 months, followed by 60mg per day for another 3
months, (ii) 160mg per day of valsartan for 6 months. Though it was
found that TW extract contributed to significant reduction of urine
protein levels, there were several reported adverse effects, such as hy-
perkalaemia, decrease in white blood cell count, vomiting, as well as
liver impairment [20,90].
In short, though TW plant extracts provide substantial therapeutic
benefits, inappropriate usage of the herb may lead to severe con-
sequences, in which diarrhoea, nausea, and infertility are the most
commonly observed side-effects [20,59,91–95]. Therefore, the appli-
cation of TW extract for the treatment of diseases may be limited due to
its toxicological profile. (Table 2) However, as clinical experiences
suggest that TW extract possesses great therapeutic potential, and ce-
lastrol being the most abundant bioactive compound present in TW,
these pharmacological properties may circumvent its toxicological
drawbacks, which supports the growing interest on celastrol as the
future of drug development. Hence, further trials may be conducted to
provide a clear insight on the safety profile of celastrol, as well as to
determine its optimum dosage of this compound.
3. Conclusions
Based on the evidences from studies performed by different re-
searchers over the years, celastrol has indubitably a diversity of phar-
macological actions that are modulated by various molecular targets
and signalling pathways. In spite of that, further studies on the phar-
macokinetic properties of celastrol have to be done in order to establish
a clear safety profile of celastrol, followed by well-designed clinical
trials to evaluate the efficacy of celastrol for the therapeutic use in
humans, which paves a new path in the field of drug discovery and
development.
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